The production of pharmaceutical ingredients may become a gateway for Ukrainian medicines to Europe: the Cabinet outlined the strategy
The Ukrainian pharmaceutical industry has a chance to significantly strengthen its position in the European market through the development of active pharmaceutical ingredient production. This direction will not only reduce dependence on imported raw materials but also promote the creation of joint production chains between Ukraine and EU countries. The government is confident that this could become one of the key factors in integrating Ukrainian manufacturers into the European pharmaceutical space.
The development of active pharmaceutical ingredient (API) production in Ukraine will contribute to the formation of reliable supply chains and help Ukrainian pharmaceutical companies enter the European Union market. This position was expressed by Deputy Prime Minister for European and Euro-Atlantic Integration Taras Kachka.
According to him, Ukraine needs to pay special attention to the development of API production, as this will allow building a unified pharmaceutical production chain with the EU. This approach should strengthen cooperation between Ukrainian and European manufacturers and make them more competitive in the global market.
Kachka emphasized that the Ukrainian pharmaceutical market does not pose a threat to European manufacturers. On the contrary, involving Ukrainian companies in the joint production process can provide the EU with additional competitive advantages globally.
He also expressed confidence that Ukrainian manufacturers will be able to take advantage of the opportunities opened by European integration and, in the medium term, become reliable partners for European business. As a result, a united European-Ukrainian pharmaceutical market may be formed, where parties will work as partners.
At the same time, the official noted that business concerns about adapting to EU rules may have a positive effect on the industry's development. In his opinion, it is important for the state to assess which EU requirements truly create additional costs for enterprises and which stimulate production modernization and quality improvement.
In particular, for the pharmaceutical industry, EU requirements regarding good manufacturing practice (GMP), the implementation of 2D coding, and other regulatory standards are seen by him as investments in production development. Despite ongoing market discussions about certain innovations, he believes such requirements contribute to increasing the competitiveness of enterprises.
Kachka also stressed that he does not see any European norms or rules that could threaten the business models of Ukrainian pharmaceutical manufacturers. On the contrary, harmonization with EU standards, in his opinion, opens additional opportunities for the industry's development and integration into the common European market.
Subscribe to our Telegram channel t.me/sudua and to Google News SUD.UA, as well as to our VIBER and WhatsApp, our page on Facebook and on Instagram to stay informed about the most important events.
